A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABT-165, a Dual Variable Domain Immunoglobulin in Subjects With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Jul 2017
At a glance
- Drugs ABT 165 (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 11 Jul 2017 Planned End Date changed from 29 Jun 2018 to 13 Feb 2018.
- 11 Jul 2017 Planned primary completion date changed from 29 Jun 2018 to 13 Feb 2018.
- 11 Jul 2017 Status changed from recruiting to active, no longer recruiting.